Values First Advisors Inc. Has $2.12 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Values First Advisors Inc. raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,992 shares of the biopharmaceutical company’s stock after purchasing an additional 202 shares during the quarter. Alnylam Pharmaceuticals accounts for approximately 1.2% of Values First Advisors Inc.’s investment portfolio, making the stock its 17th biggest position. Values First Advisors Inc.’s holdings in Alnylam Pharmaceuticals were worth $2,116,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Jennison Associates LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $61,160,000. Strategic Financial Concepts LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $41,529,000. Los Angeles Capital Management LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 11,433.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after acquiring an additional 135,829 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $578,000. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Alnylam Pharmaceuticals by 13.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company’s stock valued at $4,687,000 after acquiring an additional 2,285 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ALNY. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. TD Cowen raised their price objective on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a report on Monday, October 21st. StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. Finally, Barclays raised their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $298.61.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $268.99 on Wednesday. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The firm has a market capitalization of $34.69 billion, a price-to-earnings ratio of -102.67 and a beta of 0.35. The business has a 50-day simple moving average of $253.54 and a 200 day simple moving average of $262.97. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the sale, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at $19,797,302.40. The trade was a 6.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CMO Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the transaction, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at $3,416,865. This trade represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 73,964 shares of company stock valued at $20,622,925 in the last three months. Corporate insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.